BioStock: Cereno’s CEO comments on progress with CS1 and CS014

Cereno Scientific reports new advancements with two of its drug candidates. The phase II study with CS1 in pulmonary arterial hypertension (PAH) has closed patient recruitment, and topline results will be presented in the third quarter of 2024. Furthermore, the first patient has been dosed in the phase I study with CS014, which is being developed for thrombosis prevention. BioStock reached out to CEO Sten R. Sörensen to learn more.

Read the interview at biostock.se:

https://www.biostock.se/en/2024/07/cerenos-ceo-comments-on-progress-with-cs1-and-cs014/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/